WCG Clinical

NOVEMBER 17, 2023

This change expanded the definition of HGT research to include research using nucleic acids that are able to replicate, be transcribed, translated into protein, and/or integrate into the host genome. If implemented, these changes would broaden the definition of HGT to include new gene editing and genome-modified products.

Genome 52

Genome Genomics Gene Editing Genetic Engineering 52

Trialfacts

SEPTEMBER 12, 2024

About the Research Center: Boston Children’s Hospital The research enterprise at Boston Children’s Hospital, involving over 3,000 researchers, is the largest in the world at a pediatric center. This includes the pathogenesis of Atopic Dermatitis Location What’s Next?

Research 52

Research Gene Editing Biobanking Bioinformatics 52

Advarra

NOVEMBER 29, 2022

The Bespoke Gene Therapy Consortium (BGTC) 2 aims to overcome major obstacles and streamline the development process for small-batch gene therapies. The BGTC will act as a traffic light for these therapies, providing information on basic and clinical research, manufacturing, production, and regulatory requirements.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

XTalks

FEBRUARY 27, 2024

There have been significant advancements in new rare disease drugs, particularly for genetic disorders that can be treated by correcting, replacing or silencing defective genes. The US Food and Drug Administration (FDA) has approved a number of new rare disease drugs in recent years, including gene therapies.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

The Pharma Data

JANUARY 10, 2021

Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the Company can begin dosing patients. Clinical trial materials are being manufactured by Editas Medicine.

Medicine 52

Medicine Development Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 20, 2023

This may lead to therapies and dosing regimes being less suitable for minority populations – and according to Hans Bunschoten, chief strategy officer at clinical research company Cerba Research, part of Cerba Healthcare, this is a major problem. The technology platforms are almost the same.

Research 130

Research Clinical Trials Clinical Trials Trials 130

The Pharma Data

JANUARY 24, 2021

It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate.

Trials 52

Trials Allergies In-Vitro Antibody 52